Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three kinds of virus hepatitis are recognized today: hepatitis A, B, and "non A-nonB". Hepatitis A is transmitted mainly by the anal-oral route, hepatitis B and probably also the third form of hepatitis principally by direct inoculation or close physical contact. Normal human immune serum globulin protects against hepatitis A, but only gives limited protection against hepatitis B and "non A-non B" hepatitis. Special immune serum globulin provides better protection but it is only available in small quantities and should be reserved for direct inoculation only. Vaccines for active immunization against hepatitis A and "non A- non B" hepatitis have not yet been developed and active immunization against hepatitis B with HBs-Ag is still in the experimental stage.
 ...
PMID:[Hepatitis: an international problem (author's transl)]. 6 Jun 98

Immune serum globulin prophylaxis for foreign travellers should be reserved for those at high risk having no immunity against hepatitis A. In this study from Sweden the incidence of tourist hepatitis in different age groups was correlated to the prevalence of antibodies to hepatitis A virus (anti-HAV) in the population. 58% of individuals over 50 years had anti-HAV and travellers in these ages seldom experienced "tourist hepatitis". In younger age groups a low prevalence of anti-HAV (11%) was combined with a higher incidence of tourist hepatitis.
 ...
PMID:Tourist hepatitis, antibodies to hepatitis A virus and immune serum globulin prophylaxis. 21 56

Serum proteins and immunoglobulins were investigated in children with infectious mononucleosis. The results were as follows: 1. Most striking changes in serum protein patterns were increased levels of immunoglobulins. The resulting gammopathies are of symmetric and/or asymmetric type with a beta-gamma bridge.--2. Increased levels of immunoglobulins included all principal immunoglobulin classes IgG, IgM and IgA.--3. Polyclonal gammopathy in infectious mononucleosis did neither reflect the intensity of hepatic involvement nor was a sign for persisting or progressive hepatitis.--4. The type of gammopathies found seems to justify those clinicians, who did not consider to be usefull the application of gammaglobulin in the course of infectious mononucleosis. 5. Suggestion. If it is correct to assume according to Benyeschel-Melnick et al., that the raised production of antibodies in infectious monucleosis limits the further course of the disease, and is the defense against the development of leukemia, it would be necessary to reevaluate the application of corticoid therapy in infectious mononucleosis. This therapy should be reserved for life threatening complciations only.
 ...
PMID:[ Polyclonal gammopathy in children with infectious mononucleosis (author's transl)]. 100 9

Three cases of children who developed hepatic toxicity of different degree while on antituberculous treatment with isoniazid and rifampicin are reported. The clinical picture is presented and the pathogenesis of the hepatic damage is discussed. The pathological findings in the liver are those of a drug induced hepatitis. The combined treatment of tuberculosis in children with isoniazid and rifampicin is potentially dangerous and should be reserved for cases in which resistance to other drugs has been demonstrated.
 ...
PMID:Hepatic toxicity of antituberculous drugs in children. 101 83

Factor IX concentrates are of paramount importance in the treatment of hemophilia B. Growing reports of thromboembolic complications and of disseminated intravascular coagulation, coupled with the danger of hepatitis transmission, suggest that the concentrates should be primarily reserved for the treatment of hemophilia B. Concise guidelines for treatment are presented.
 ...
PMID:[Clinical use of factor IX concentrates]. 121 1

Sixty cases of pregnancy with thrombocytopenia were analyzed. Bleeding syndrome was found in 36 patients during pregnancy, with 7 cases suffering from massive hemorrhage during delivery and a postpartum hemorrhage rate of 11.7%. There was a negative correlation between the platelet level and the amount of bleeding during gestation and delivery. We suggest that cortico steroid is necessary with a platelet count less than 50 x 10(9)/L in the middle or late trimester of pregnancy to reduce the bleeding tendency during delivery, as well as the incidence of thrombocytopenia in the newborn infant use of excessive platelet transfusion is not encouraged, since it implicates an increase in antibody-induction (PAIG) and probability of C type hepatitis in the recipient. Platelet transfusion should be reserved only for the treatment of serious hemorrhage. There were 53 newborn infants, 7 of whom (13.2%) suffered from thrombocytopenia, with a mortality of 1.9% (7/53) during the perinatal.
 ...
PMID:[Clinical analysis of 60 cases of pregnancy with thrombocytopenia]. 129 Dec 20

Listeria monocytogenes is a Gram-positive bacillus that is pathogenic in both the normal and compromised host. We describe Listeria peritonitis and cerebritis in a patient with cirrhosis due to non-A, non-B hepatitis, and review the 11 other cases of Listeria peritonitis reported in the English-language literature. Listeria is a rare cause of peritonitis in debilitated, older patients, with two-thirds of the cases occurring in patients with chronic liver disease. Listeria peritonitis may also occur in patients undergoing peritoneal dialysis, or in those with malignancy. Peritonitis due to Listeria is clinically similar to spontaneous bacterial peritonitis, and is associated with fever, variable abdominal pain, and neutrocytic ascites; bacteremia commonly accompanies Listeria peritonitis. This syndrome can be successfully treated with antimicrobial drugs, although the third-generation cephalosporins commonly used in the therapy of spontaneous bacterial peritonitis are not recommended. Ampicillin may be the drug of choice, with combination therapy with an aminoglycoside reserved for cases that do not respond to ampicillin alone.
 ...
PMID:Listeria monocytogenes peritonitis: case report and literature review. 144 54

Management of the pediatric renal-transplant recipient requires careful pretransplant evaluation including psychosocial assessment and cautious donor/recipient selection. Early transplantation is preferable in infants less than 1 year of age if a suitable live-related donor is available. However, cadaveric-allograft transplantation is best reserved for patients older than 3 years with donors older than 5 years. Pre-emptive transplantation is suitable for approximately one fifth of the population. Medical preparation includes careful HLA-A, -B, and -DR loci matching, interferon treatment for positive hepatitis antigenemia, and acyclovir prophylaxis for a cytomegalovirus (CMV) antibody-negative patient to a seropositive donor. Postoperative management requires close monitoring of the patient's volume status with careful fluid replacement in the form of colloid and crystalloid. Immunosuppression involves multiple drug regimens that include corticosteroids, ciclosporin, azathioprine, antilymphocyte (or -thymocyte) globulin (ALG/ATG), monoclonal antibodies (OKT3), and a ciclosporin alternative: FK-506. Long-term complications dictate management and are divided into medical, surgical, immune, and infectious categories. These are predominated by treatment of acute and chronic rejection, hypertension, and CMV infection.
 ...
PMID:Clinical management of the pediatric renal-allograft recipient. 166 34

The expression "immunocompromised host" refers to an individual who has one or more defects in the body's natural defense, which leads to severe, often life-threatening, infections. Alcoholism, diabetes mellitus, advanced age, the use of antacids, and viral infections have immune-modulating effects. The human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus, and Non A, Non B hepatitis virus also contribute to immunosuppression. The lung has a special vulnerability to infection, and pneumonia accounts for more than 40% of deaths in the immunosuppressed population. Diagnostic methods include detection of microbial antigens by monoclonal antibodies, DNA sequences by the polymerase chain-reactions or DNA probes, and unique metabolites of pathogens by gas chromatography. Transtracheal aspiration was used to obtain uncontaminated respiratory secretions, but fiberoptic bronchoscopy with shielded brush and bronchoalveolar lavage (BAL) is a better means of diagnosis because of a 90% sensitivity in diagnosing pneumocystis infection. Percutaneous aspiration and open lung biopsy are reserved for more complicated cases. Empiric treatment is justified in far advanced AIDS or relapsed myelogenous leukemia with limited life expectancy, or when there is uncontrollable bleeding diathesis or impaired pulmonary function as invasion diagnostic procedures will not be tolerated. The most important antiinfective measure is careful hand washing, while prophylactic antibiotics, selective decontamination, and antifungal, antiviral, and antiparasitic agents can be used. Active and passive immunization against specific pathogens, immunological reconstitution with granulocyte-macrophage colony-stimulating factor (GM-CSF) and reducing the dosage of immunosuppression are the other strategies for prevention. In the last several decades there has been substantial progress in the management of chronic diseases which used to be fatal.
 ...
PMID:Pulmonary infections in the immunocompromised host. 166 54

In summary, the role of fibronectin in clinical medicine is not yet certain. Correlation of sepsis and organ failure with decreased fibronectin levels is still to some degree questionable; controlled clinical trials are urgently needed. The risk of hepatitis, AIDS, and other transfusion-transmitted diseases must be balanced by data substantiating the clinical efficacy of fibronectin therapy. To date, no results from controlled trials using purified fibronectin have been reported. Final judgement must be reserved pending results of appropriate human studies. It is likely, however, that even if fibronectin is proven to be clinically useful, the patient population which will achieve some benefit from its use will be restricted to septic and/or critically ill patients. As noted by Mosher and Grossman however, physicians treating such patients would likely welcome any new and effective therapeutic intervention.
 ...
PMID:Fibronectin: applications to clinical medicine. 351 68


1 2 3 4 Next >>